AzTrials
AzTrials

Post Operative Pain, AcutePhase 4NCT05565235

Comparing Efficacy of Different Drugs Combinations for Serratus Anterior Block for Thoracotomy

A Phase 4 study testing patients will receive intraoperative serratus block with bupivacaine, serratus block with bupivacaine /magnesium and serratus block with bupivacaine with nalbuphine in people with Post Operative Pain, Acute, run by Cairo University at 1 site in Egypt.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

We aim to compare efficacy and efficiency of serratus anterior block with bupivacaine alone to bupivacaine/magnesium and bupivacaine /nalbuphine in postoperative analgesia for thoracotomy surgery. Read more about this study

Who is it for?
Ages 16 to 65 years
Conditions the study is for
Post Operative Pain, Acute
What is being tested?
patients will receive intraoperative serratus block with bupivacaine, serratus block with bupivacaine /magnesium and serratus block with bupivacaine with nalbuphine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
78 participants
Where
1 siteEgypt
Study dates
9 Dec 2022to 10 Nov 2023
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 16 to 65 years
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Elective thoracotomy or unplanned thoracotomy after failed thoracoscopic surgery
  • Patient with American Society of Anesthesiology ASA I, II or III.

Who cannot join

  • Patient refusal
  • Contraindication for regional anesthesia
  • Allergy from local anesthetics
  • Bleeding diathesis (Bleeding tendency with prothrombin concentration PC less than 75 % or platelet count less than 50,000/µL.
  • Use of anticoagulants, infection at the puncture site.
  • Presence of severe Chronic renal impairment or acute renal failure, decompensated liver disease, cardiac or psychiatric disorders, GIT ulcers, communication barriers, hearing deficit or high grades of visual deficit that interfere with consenting, VAS assessments, and delirium, or another cognitive dysfunction.
Show all 11Show fewer
  • Patient intubated preoperatively.
  • Patient will not be extubated immediately postoperatively
  • Opioid tolerant patients.
  • Any contraindications of Magnesium infusion as hypovolemia or severe impaired ventricular systolic function.
  • Contraindication of acetaminophen and Diclofenac sodium administration.

Trial locations and contacts

1 site in 1 country.

Egypt1 site, 1 recruiting
  • Kasr Alainy

    Cairo, 11562

    Ahmed H. Sayed, M.D, +201068112464, drahmedhusseinanesth87@gmail.com

    Tamer M. Atteya, M.D, +201223444664, Tameratteya_1980@live.com

    Recruiting

Other trials in Egypt

About this study

Official title: Efficacy of Serratus Anterior Plane Block Using Bupivacaine Alone, Bupivacaine/ Magnesium Sulfate Versus Bupivacaine/ Nalbuphine for Thoracotomy: A Randomized, Double-Blinded Comparative Study.

We aim to compare efficacy and efficiency of serratus anterior block with bupivacaine alone to bupivacaine/magnesium and bupivacaine /nalbuphine in postoperative analgesia for thoracotomy surgery.

Objectives:

Read more

To compare bupivacaine alone, bupivacaine/magnesium and bupivacaine /nalbuphine in serratus anterior plane block for intraoperative and postoperative analgesia for thoracotomy surgery.

  • The time for 1st rescue analgesia.
  • Calculation of the opioid requirements; (the total intra-operative post-operative morphine consumption in first 24h postoperative).
  • Assessment of pain score (VAS)- rest, VAS-movement, VAS-cough during post-operative 24hrs period.

Hypothesis:

We hypothesize that magnesium sulfate and nalbuphine can reduce acute postoperative pain and result in efficacious postoperative analgesia due to block of the lateral cutaneous branches of the intercostal nerves (T2 - T6) by diffusion across the inter-fascial planes.

Read the detailed description
  1. Study design prospective, randomized controlled study. II. Study setting and location It will be conducted at El Kasr Al-Aini hospitals, cardiothoracic Surgery, Cairo University.after registration in clinicaltrials.gov and getting a unique number III. Study population patients of both genders, aged (16 - 65) years old, ASA I, II or III scheduled for elective general thoracotomy surgeries will be included. Consenting patients will be randomly allocated to one of three groups: Group B: patients will receive intraoperative serratus block with bupivacaine. Group BMG: patients will receive intraoperative serratus block with bupivacaine/ magnesium.

Group BN: patients will receive intraoperative serratus block with bupivacaine /nalbuphine.

  1. Study Procedures
  2. Randomization: The patients will be randomized using a computer-generated list of random numbers which will be sealed in closed envelopes. Patients will be randomly allocated to one of the three groups. The study drugs are going to be prepared by anesthetist (who were blinded to the study and did not share in the technique) in labelled syringes, patients into 3 groups by a sealed opaque envelope, and received the study drug as follows: group B (n = 26): (bupivacaine): received bupivacaine 30 mL 0.25%, group BMG (n =26): received bupivacaine 30 mL 0.25% and 500 mg magnesium sulphate. Group BN (n =26): (bupivacaine/nalbuphine): received bupivacaine 30 mL 0.25 % and nalbuphine 0.2 mg/kg.
  3. Study Protocol All patients will be assessed clinically and investigated for exclusion of any of the above-mentioned contraindications.

Laboratory work needed will be: Complete blood count (CBC); prothrombin time and concentration (PT\& PC, INR), renal functions and liver function tests or other necessary investigation for the desired surgery. ECG, CXR, CT chest and echocardiography will be done if needed preoperatively Anesthetic application

  • Standard monitoring procedures will include continuous ECG, pulse oximetry, invasive arterial blood pressure, end-tidal CO2, inhaled gas analyzer and temperature monitoring. Baseline readings (T0) of heart rate, systolic, diastolic, and mean blood pressure are going to be record after monitor attachment and every 30 min
  • General anesthesia will be induced in all groups (B, BN, AND BMG group) using fentanyl 2 mic/kg, propofol 2 mg/kg and atracurium 0.5 mg/kg while in obese patients Lean body weight (LBW) will be used. single or double lumen tube will be used as preferred by surgeon, Anesthesia will be maintained using isoflurane (1 MAC) and atracurium supplements were given to maintain muscle relaxation., diclofenac 75mg once iv infusion and acetaminophen 15 mg/kg. Additional dose of fentanyl 1mic / kg will be given if there is tachycardia >100 or intraoperative hypertension more than 20% of the preoperative value. In addition to, all patients will receive cefotaxime 50 mg/kg.

Near the end of surgery, the surgeon is going to aspirate the content of the labelled syringes with a sterile one and ask to inject it below the serratus anterior muscle after closing it. To prevent inadvertent intravascular insertion of the needle, the study drugs are going to be injected in increments after repeated aspiration. At the end of the surgery, inhaled anesthetic is going to discontinue. After the reversal of muscle relaxation and full recovery, patients will be monitored at the recovery unit. Postoperative pain Visual Analogues Scales (VAS, VAS movement, VAS cough) are going to be measure pain (static, dynamic and with cough respectively), where 0 = "no pain" and 10 = "worst pain imaginable", at 1, 6, 12, 24 h by a person not oriented by protocol. Classic postoperative analgesic regimen (Diclofenac 75mg every 8hrs and acetaminophen 1gm every 6 hrs.). The efficacy of the block will be test by measuring the distribution of lost cold sensation along distribution of lateral cutaneous nerve from second intercostal to ninth intercostal nerve.

Morphine 2 mg Iv incremental boluses will be given as rescue analgesia for patients if VAS score >3.

  1. Measurement tools
  • Demographic data (age, sex, BW) patient surgery characteristic (duration of the surgery, type of operation) and ASA status will be recorded.
  • In the PACU and the ward, patient will be assessed for the first 24 hours post-operative period using (VAS score) for Pain assessment.

Blood pressure (SBP, DBP and MAP) and heart rate will also be recorded during the operation and the first 24 hours post-operative period and intraoperative fentanyl doses.

Statistical Analysis I. Sample size The time of 1st use of rescue analgesia post-operatively is defined as the primary outcome of the study using one-way ANOVA test. As based on previous study (Comparison of ultrasound-guided serratus plane block and thoracic paravertebral block for postoperative analgesia after thoracotomy, a randomized controlled trial Research and Opinion in Anesthesia \& Intensive Care 2018, 5:314-322), the mean time to 1st use of morphine was (6.2 ± 1.66) hours.

If combining the bupivacaine with nalbuphine or with magnesium would result in a 30% increase in the time to 1st use of morphine: α error of 0.05 and power of 0.95. A minimum of 78 patients was calculated (27 patients in each group). sample size was calculated using G-Power version 3.1.9.2 software.

II. Statistical analysis

Analysis of data will be performed using Statistical package for social science (SPSS) software, version 15 for Microsoft Windows (SPSS Inc., Chicago, IL, and USA). Categorical data will be reported as numbers and percentages and will be analyzed using chi-squared test. Continuous data will be checked for normality using Kolmogorov-Smirnov test. Normally distributed data will be presented as means (standard deviations) and will be analyzed using unpaired student t-test. Skewed data will be expressed as medians (quartiles) and will be analyzed using Mann Whitney U test. For repeated measures, a two-way repeated measure ANOVA will be used to evaluate the block (between-groups factor) and the time (repeated measures)". Post-hoc pairwise comparison will be performed using Bonferroni test. P value of 0.05 or less will be considered significant.

Being tested
patients will receive intraoperative serratus block with bupivacaine, serratus block with bupivacaine /magnesium, serratus block with bupivacaine with nalbuphine
Keywords
thoracotomy, serratus anterior plane block
Medical subject headings
Pain, Postoperative

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • patients will receive intraoperative serratus block with bupivacaineDrug

    no additives

  • serratus block with bupivacaine /magnesiumDrug

    magnesium added

  • serratus block with bupivacaine with nalbuphineDrug

    nalbuphine added

Study groups in NCT05565235
Study groupRoleWhat they receive
Group BActive comparatorbupivacaine
Receives: Drug: patients will receive intraoperative serratus block with bupivacaine
Group BMGActive comparatorbupivacaine/ magnesium.
Receives: Drug: serratus block with bupivacaine /magnesium
Group BNActive comparatorbupivacaine /nalbuphine.
Receives: Drug: serratus block with bupivacaine with nalbuphine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The time of 1st rescue analgesia post operative

    if VAS or VAS-movement >3.

    Measured: one year

Secondary outcomes (4)
  1. Pain assessment score; (VAS score) VAS-movement and VAS-cough

    at 1, 6, 12, 24 hours post-operative period

    Measured: one year

  2. Total amount of morphine (mg) used in 24h post operatively

    when VAS >3

    Measured: one year

  3. Hemodynamic changes (SBP, DB, MAP)

    during the first 24 hours in the postoperative period

    Measured: one year

  4. Incidence of local anesthetic toxicity.

    Measured: one year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Oct 2022
  2. Study start9 Dec 2022
  3. Primary completion10 Sep 2023 (estimated)
  4. Study completion10 Nov 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
78 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05565235
Sponsor's protocol ID
N-50-2022
Status last verified
Dec 2022
First submitted
30 Sep 2022
Last updated
13 Dec 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Gerner P. Postthoracotomy pain management problems. Anesthesiol Clin. 2008 Jun;26(2):355-67, vii. doi: 10.1016/j.anclin.2008.01.007.

    PubMed 18456219
  • Kavanagh BP, Katz J, Sandler AN. Pain control after thoracic surgery. A review of current techniques. Anesthesiology. 1994 Sep;81(3):737-59. doi: 10.1097/00000542-199409000-00028. No abstract available.

    PubMed 8092520
  • Katz J, Jackson M, Kavanagh BP, Sandler AN. Acute pain after thoracic surgery predicts long-term post-thoracotomy pain. Clin J Pain. 1996 Mar;12(1):50-5. doi: 10.1097/00002508-199603000-00009.

    PubMed 8722735
  • Kaushal B, Chauhan S, Saini K, Bhoi D, Bisoi AK, Sangdup T, Khan MA. Comparison of the Efficacy of Ultrasound-Guided Serratus Anterior Plane Block, Pectoral Nerves II Block, and Intercostal Nerve Block for the Management of Postoperative Thoracotomy Pain After Pediatric Cardiac Surgery. J Cardiothorac Vasc Anesth. 2019 Feb;33(2):418-425. doi: 10.1053/j.jvca.2018.08.209. Epub 2018 Aug 31.

    PubMed 30293833
  • Semyonov M, Fedorina E, Grinshpun J, Dubilet M, Refaely Y, Ruderman L, Koyfman L, Friger M, Zlotnik A, Klein M, Brotfain E. Ultrasound-guided serratus anterior plane block for analgesia after thoracic surgery. J Pain Res. 2019 Mar 11;12:953-960. doi: 10.2147/JPR.S191263. eCollection 2019.

    PubMed 30881105
  • De Oliveira GS Jr, Castro-Alves LJ, Khan JH, McCarthy RJ. Perioperative systemic magnesium to minimize postoperative pain: a meta-analysis of randomized controlled trials. Anesthesiology. 2013 Jul;119(1):178-90. doi: 10.1097/ALN.0b013e318297630d.

    PubMed 23669270
  • Chawda PM, Pareek MK, Mehta KD. Effect of nalbuphine on haemodynamic response to orotracheal intubation. J Anaesthesiol Clin Pharmacol. 2010 Oct;26(4):458-60.

    PubMed 21547169

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing patients will receive intraoperative serratus block with bupivacaine, serratus block with bupivacaine /magnesium and serratus block with bupivacaine with nalbuphine in people with Post Operative Pain, Acute, run by Cairo University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 13 Dec 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Ahmed H. Sayed, M.D (+201068112464, drahmedhusseinanesth87@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The time of 1st rescue analgesia post operative (time frame: one year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05565235, which also lists 7 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Dec 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in